Pharmafile Logo

Research conducted for Johnson and Johnson published in scientific journal

April 17, 2024 |  

Findings from a study conducted by Dr. Chris Gaj, Vice President at Research Partnership, has been published in Clinical Genitourinary Cancer.

- PMLiVE

The study, led by Johnson and Johnson, explored using real world evidence collected by patient records from physicians to examine the impact of genetic mutations on response to therapy in urothelial carcinoma.

The paper is titled ‘Prognostic Value of Fibroblast Growth Factor Receptor Genetic Alterations in Metastatic Urothelial Carcinoma’ and was published in Clinical Genitourinary Cancer. It explores the impact of FGFR mutations on response to different first-line anti-tumor regimens treating locally advanced or metastatic urothelial carcinoma. A total of 104 physicians treating first-line locally advanced or metastatic patients with systemic therapy contributed a total of 414 eligible patient records for the real-world evidence study. Findings showed that although FGFR mutations did not impact the overall progression free survival relative to wild type FGFR patients, the subset of gene mutation patients who received first-line immune checkpoint inhibitors without chemotherapy had significantly higher rates of progression relative to wild type patients receiving immune checkpoint inhibitors without chemotherapy.

For this project, Research Partnership was responsible for the survey design, enrolling respondents via fieldwork partners, performing analysis, both internally and with an external statistical analysis partner, as well as reading and approving drafts of the manuscript. We were privileged to assist our partners as they work to better understand responses to anti-tumor therapy in this malignancy and help oncologists refine the optimal treatment for patients.

Find out more and read the full publication. 

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

A guide to measuring and tracking brand KPIs

Dr Allison Fleetwood, Director of Therapy Watch, alongside Associate Director Jennifer Redfearn, recently delivered a workshop on measuring and tracking brand KPIs as part of the BHBIA training programme (www.bhbia.org.uk).

Electronic medical records and doctor/patient communication

View from the US: When I talk to family members or friends who are physicians these days, I hear a lot of complaints.

Statistics and bikinis – 2 men united

I want to write today about 2 men that between them have reminded me of a fine line that we have to tread every time we analyse a dataset...

Eliminating Stigma: A consideration of the role the pharmaceutical industry can play

My recent article in Medical Marketing & Media explored the importance of vaccine perceptions in a self-pay market and touched upon the issue of stigma, with the recognition that some diseases or...

Fighting talk

One thing that grasps my interest is how society has adopted military style language when talking about cancer

Is MINT the next BRIC?

In 2001, British economist Jim O’Neill coined the now ubiquitous acronym ‘BRIC’, to stand for the four emerging economies of Brazil, Russia, India and China, which he suggested were all...

The healthcare market research themes for 2014

As we shake off our winter coats and prepare for what will hopefully be a long, hot summer, the 2014 themes for healthcare and market research are emerging.

Big Data—a new player in the Healthcare Industry

Big Data is an exciting by-product of the information technology revolution and offers new ways of understanding customers.

Blog: Affordable Care Act

What does the future hold for the US pharma industry?

Webinar: How to conduct effective market research in emerging markets

Pharmaceutical market research is still evolving in many emerging markets and so finding the insights you require can be a challenge.